Enanta Pharmaceuticals | ENTA - Gross Profit On Sales

Stock Price
14.98
Daily Change
-0.43 -2.79%
Monthly
10.88%
Yearly
108.64%
Q1 Forecast
13.86

Enanta Pharmaceuticals reported -22.29M in Gross Profit on Sales for its fiscal quarter ending in December of 2024.





Gross Profit On Sales Change Date
AbbVie USD 10.47B 605M Sep/2025
Amgen USD 6.48B 307M Sep/2025
Anika Therapeutics USD 14.68M 9.46M Mar/2025
Arrowhead Research USD 256.47M 228.7M Sep/2025
AstraZeneca USD 12.39B 5M Dec/2025
BioCryst Pharmaceuticals USD -88.88M 202.74M Dec/2024
Biogen USD 1.65B 34.6M Dec/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Enanta Pharmaceuticals -22.29M 23.75M Dec/2024
Gilead Sciences USD 6.31B 106M Dec/2025
GlaxoSmithKline GBP 6.18B 106M Dec/2025
Halozyme Therapeutics USD 281.77M 2.41M Sep/2025
Heron Therapeutics USD 23.35M 1.6M Sep/2024
Immunic 0 0 Mar/2025
Incyte USD 1.39B 118.68M Dec/2025
Insmed USD 217.69M 106.25M Dec/2025
Ionis Pharmaceuticals USD 195M 40M Dec/2025
J&J USD 16.6B 118M Dec/2025
Karyopharm Therapeutics USD -30.78M 1.29M Dec/2024
Ligand Pharmaceuticals USD 155.28M 82.42M Sep/2025
Merck USD 13.42B 431M Sep/2025
Neurocrine Biosciences USD 787.9M 7M Dec/2025
Novartis USD 10.82B 695M Sep/2025
Novavax USD 23.89M 239.21M Sep/2024
Pfizer USD 3.54B 7.61B Sep/2025
PTC Therapeutics USD 148.38M 39.31M Dec/2025
Roche Holding CHF 22.09B 10.04B Dec/2025
Sarepta Therapeutics USD 43.55M 204.36M Dec/2025
Vertex Pharmaceuticals USD 2.72B 62.4M Dec/2025